Regorafenib plus FOLFIRI with irinotecan dose escalated according to uridine diphosphate glucuronosyltransferase 1A1genotyping in previous treated metastatic colorectal cancer patients:study protocol for a randomized controlled trial

Regorafenib plus FOLFIRI with irinotecan dose escalated according to uridine diphosphate glucuronosyltransferase 1A1genotyping in previous treated metastatic colorectal cancer patients:study protocol for a randomized controlled trial

Abstract Background Regorafenib is an oral multikinase inhibitor for metastatic colorectal cancer (mCRC) previously treated with fluoropyrimidines, irinotecan, oxaliplatin, monoclonal antibodies targeting vascular endothelial growth factor, and monoclonal antibodies targeting epidermal growth factor...

Full description

Bibliographic Details
Main Authors: Cheng-Jen Ma, Tsung-Kun Chang, Hsiang-Lin Tsai, Wei-Chih Su, Ching-Wen Huang, Yung-Sung Yeh, Yu-Tang Chang, Jaw-Yuan Wang
Format: Article
Language:English
Published: BMC 2019-12-01
Series:Trials
Subjects:
Regorafenib
UGT1A1
FOLFIRI
Dose escalation
Metastatic colorectal cancer
Online Access:https://doi.org/10.1186/s13063-019-3917-z

Similar Items

Similar Items